Journal of AIDS and HIV Research
Subscribe to JAHR
Full Name*
Email Address*

Article Number - 24E08CE62105


Vol.9(1), pp. 17-30 , January 2017
DOI: 10.5897/JAHR2016.0406
ISSN: 2141-2359



Full Length Research Paper

Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic



Tariro Dianah Chawana*
  • Tariro Dianah Chawana*
  • Department of Clinical Pharmacology, University of Zimbabwe, Harare 00263, Zimbabwe
  • Google Scholar
David Katzenstein
  • David Katzenstein
  • Department of Medicine, Division of Infectious Diseases, Stanford University, California.
  • Google Scholar
Kusum Nathoo
  • Kusum Nathoo
  • Department of Paediatrics, University of Zimbabwe, Harare 00263, Zimbabwe.
  • Google Scholar
Bernard Ngara
  • Bernard Ngara
  • Department of Community Medicine, University of Zimbabwe, Harare 00263, Zimbabwe.
  • Google Scholar
Charles Fungai Brian Nhachi
  • Charles Fungai Brian Nhachi
  • Department of Clinical Pharmacology, University of Zimbabwe, Harare 00263, Zimbabwe
  • Google Scholar







 Received: 17 November 2016  Accepted: 07 December 2016  Published: 31 January 2017

Copyright © 2017 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


Sustaining virological suppression among HIV-infected adolescents is challenging. We evaluated a home-based adherence intervention and characterized self-reported adherence, virological response and drug resistance among adolescents failing atazanavir/ritonavir (ATV/r)-based 2nd line treatment. Methods: HIV-positive adolescents (10-18 years) on ATV/r-based 2nd line treatment with virological failure (viral load (VL) ≥1 000 copies/ml) were randomized to either standard care (SC) or SC with addition of modified directly administered antiretroviral therapy (mDAART) for 90 days. VL was measured and questionnaires were administered at study entry and at 3 months. Genotyping was done for participants with continued failure. Primary outcome was suppression to VL < 1 000 copies/ml. Results: Fifty adolescents aged 10-18 years on 2nd line treatment for >180 days were enrolled, 23(46%) were randomized to mDAART and 27(54%) to SC. Fifty-four percent were female; mean age was 15.8 years; mean baseline VL was 4.8(log10) copies/ml; 40% reported adherence <80% in previous 1 month at baseline; 40% suppressed (VL <1 000 copies/ml) after follow-up. mDAART resulted in significantly increased self-reported adherence (RR= 0.1; 95% CI=0.02-0.8, p=0.023); closely following dosing schedule (RR= 4.8; 95% CI=1.6-13.8, p=0.004); VL decrease (p=0.031) and modest increase in virological suppression to <1 000 copies/ml (p=0.105). Genotyping in 28/30 participants with continued virological failure demonstrated high level atazanavir resistance (I50L, N88S and I84V) in 6(21%); 3(11%) of whom also had high level resistance to lopinavir and darunavir (V32I, I50L, I54V, 147V and V82A). Discussion: The mDAART intervention modestly improved virological suppression among adolescents with ATV/r-based 2nd line treatment failure, significantly increased self-reported adherence and decreased viral load. High level ATV/r resistance was demonstrated. Conclusion: Targeting mDAART to adolescents who are virologically failing PI-based 2nd line treatment decreases viral load and increases self-reported adherence. Early drug-resistance testing could reduce morbidity and mortality.        

Key words: Adolescents, HIV, second-line treatment failure, adherence, resistance.

Achenbach CJ, Darin KM, Murphy RL, Katlama C (2011). Atazanavir/Ritonavir-Based Combination Antiretroviral Therapy for treatment of HIV-1 Infection In Adults. Future Virol. 6(2):157-177.
Crossref

 

Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH (2007). Superiority Of Directly Administered Antiretroviral Therapy Over Self-Administered Therapy Among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clin. Infect. Dis. 45(6):770-778.
Crossref

 

Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH (2004). Developing A Directly Administered Antiretroviral Therapy Intervention For HIV-Infected Drug Users: Implications For Program Replication. Clin. Infect. Dis. 38(S5):S376-S387.
Crossref

 

Amico KR, Harman JJ, Johnson BT (2006). Efficacy Of Antiretroviral Therapy Adherence Interventions: A Research Synthesis Of Trials, 1996 To 2004. J. Acquir. Immune. Defic. Syndr. 41(3):285-297.
Crossref

 

Barfod TS, Sorensen HT, Nielsen H, Rodkjaer L, Obel N (2006). 'Simply Forgot' Is The Most Frequently Stated Reason For Missed Doses of HAART Irrespective of degree of adherence. HIV Med. 7(5):285-290.
Crossref

 

Berg KM, Litwin A, Li X, Heo M, Arnsten JH (2011). Directly Observed Antiretroviral Therapy Improves Adherence And Viral Load In Drug Users Attending Methadone Maintenance Clinics: A Randomized Controlled Trial. Drug Alcohol Depend. 113(2-3):192-199.
Crossref

 

Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, Labib Maskimos EEF, Balinda SN, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Stevens W, Rinke De Wit TF, Sigaloff KCE (2016). Protease Inhibitor Resistance In The First 3 Years Of Second-Line Antiretroviral Therapy For HIV-1 In Sub-Saharan Africa. J. Infect. Dis. 214:873-883.
Crossref

 

Chawana T, Reid A, Bwakura T, Gavi S, Nhachi C (2014). Factors Influencing Treatment Failure In HIV Positive Adult Patients on First-Line Antiretroviral Therapy. Cent. Afr. J. Med. 60:5-8.

 

Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW (2000). Self-Reported Adherence to Antiretroviral Medications among Participants in HIV Clinical Trials: The AACTG Adherence Instruments. Patient Care Committee & Adherence Working Group of The Outcomes Committee Of The Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12(3):255-266.
Crossref

 

Conradie F, Wilson D, Basson A, De Oliveira T, Hunt G, Joel G, Papathanasopoulos M, Preiser W, Klausner J, Spencer D, Stevens D, Venter F, Van Vuuren C, Levin L, Meintjes G, Orrell C, Sunpath H, Rossouw T, Van Zyl G, Southern Africa HIV Clinicians Society (2012). The 2012 Southern Africa ARV Drug Resistance Testing Guidelines. South Afr. J. HIV Med. 13(4):162-167.

 

Davies MA, Boulle A, Fakir T, Nuttall J, Eley B (2008). Adherence To Antiretroviral Therapy In Young Children In Cape Town, South Africa, Measured By Medication Return And Caregiver Self-Report: A Prospective Cohort Study. BMC Pediatr. 8:34.
Crossref

 

Dong BJ, Ward DJ, Chamberlain LA, Reddy YS, Ebrahimi R, Flaherty JF, Owen WF (2016). Safety And Effectiveness Of Tenofovir/Emtricitabine Or Lamivudine Plus Ritonavir Boosted Atazanavir In Treatment Experienced HIV Infected Adults At Two Urban Private Medical Practises. J. Antivir. Antiretrovir. 4:1-5.

 

Federal Ministry of Health Nigeria (2010). National Guidelines for HIV and AIDS Treatment And Care In Adolescents And Adults 2010. Abuja, Nigeria.

 

Ferrand R, Lowe S, Whande B, Munaiwa L, Langhaug L, Cowan F, Mugurungi O, Gibb D, Munyati S, Williams BG, Corbett EL (2010). Survey of Children Accessing HIV Services In A High Prevalence Setting: Time For Adolescents To Count? Bull. World Health Organ. 88(6):428-434.
Crossref

 

Ford N, Nachega JB, Engel ME, Mills EJ (2009). Directly Observed Antiretroviral Therapy: A Systematic Review And Meta-Analysis Of Randomised Clinical Trials. Lancet 374(9707):2064-2071.
Crossref

 

Garone D, Conradie K, Patten G, Cornell M, Goemaere E, Kunene E, Kerschberger B, Ford N, Boulle A, Van Cutsen G (2014). High Rate Of Virologic Re-Suppression Among Patients Failing Second-Line Antiretroviral Therapy Following Enhanced Adherence Support: A Model of Care In Khayelitsha, South Africa. South African J. HIV Med. 14(4):166-169.

 

Goggin K, Liston RJ, Mitty JA (2007). Modified Directly Observed Therapy For Antiretroviral Therapy: A Primer From The Field. Public Health Rep. 122(4):472-481.

 

Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S (2012). Global Trends In Antiretroviral Resistance In Treatment-Naive Individuals With HIV After Rollout Of Antiretroviral Treatment In Resource-Limited Settings: A Global Collaborative Study And Meta-Regression Analysis. Lancet 380(9849):1250-1258.
Crossref

 

Harris PA, Taylor R, Thielke R, Payre J, Gonzalez N, Conde JG (2009). Research Electronic Data Capture- A Metadata-Driven Methodology And Workflow Process For Providing Translational Research Informatics Support. J. Biomed. Inform. 42(2):377-381.
Crossref

 

Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB (2013). Emergence of HIV Drug Resistance During First- And Second-Line Antiretroviral Therapy In Resource-Limited Settings. J. Infect. Dis. 207(S2):S49-S56.
Crossref

 

Kim SH, Gerver SM, Fidler S, Ward H (2014). Adherence to Antiretroviral Therapy In Adolescents Living With HIV: Systematic Review And Meta-Analysis. AIDS 28(13):1945-1956.
Crossref

 

Koole O, Denison JA, Menten J, Tsui S, Wabwire-Mangen F, Kwesigabo G, Mulenga M, Auld A, Agolory S, Mukadi YD, Van Praag E, Torpey K, Williams S, Kaplan J, Zee A, Babgsberg DR, Colebunders R (2016). Reasons for Missing Antiretroviral Therapy: Results from a Multi-Country study in Tanzania, Uganda and Zambia. PlosOne 11(1): E0147309.
Crossref

 

Lessells RJ, Avalos A, De Oliveira T (2013). Implementing HIV-1 Genotypic Resistance Testing In Antiretroviral Therapy Programs in Africa: Needs, Opportunities, and Challenges. AIDS Rev. 15(4):221-229.

 

Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, Freedberg, KA, Wood R (2012). Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy Without Resistance In A Large HIV Treatment Program In South Africa. PlosOne 7(3):E32144.
Crossref

 

Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA (2014). Perinatally Acquired HIV Infection In Adolescents From Sub-Saharan Africa: A Review Of Emerging Challenges. Lancet Infect. Dis. 14(7):627-639.
Crossref

 

Lucas GM, Mullen BA, Weidle PJ, Hader S, Mccaul ME, Moore RD (2006). Directly Administered Antiretroviral Therapy In Methadone Clinics Is Associated With Improved HIV Treatment Outcomes, Compared With Outcomes Among Concurrent Comparison Groups. Clin. Infect. Dis. 42(11):1628-1635.
Crossref

 

Macdonell K, Naar-King S, Huszti H, Belzer M (2013). Barriers to Medication Adherence In Behaviorally and perinatally infected Youth Living With HIV. AIDS Behav. 17(1):86-93.
Crossref

 

Ministry of Health Botswana 2012. Botswana National HIV And AIDS Treatment Guidelines 2012. Republic Of Botswana.

 

Modi AC, Pai AL, Hommel KA, Hood KK, Cortina S, Hilliard ME, Guilfoyle SM, Gray WN, Drotar D (2012). Pediatric Self-Management: A Framework for Research, Practice, and Policy. Pediatrics 129(2):E473-E485.
Crossref

 

Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson,RE, Regensberg L, Cotton M, Maartens G (2009). Antiretroviral Therapy Adherence, Virologic And Immunologic Outcomes In Adolescents Compared With Adults In Southern Africa. J. Acquir. Immune. Defic. Syndr. 51(1): 65-71.
Crossref

 

Nachega JB, Mills EJ, Schechter M (2010). Antiretroviral Therapy Adherence and Retention In Care In Middle-Income And Low-Income Countries: Current Status Of Knowledge And Research Priorities. Curr. Opin. HIVAIDS 5(1):70-77.
Crossref

 

National Department of Health South Africa (2012). Clinical Guidelines for the Management of HIV And AIDS In Adults And Adolescents. Pretoria, South Africa.

 

Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, Lawn SD, Wood R, Bekker LG (2012). Treatment Outcomes In HIV-Infected Adolescents Attending A Community-Based Antiretroviral Therapy Clinic In South Africa. BMC Infect. Dis. 12:21.
Crossref

 

Panel on Antiretroviral Guidelines for Adults and Adolescents (2012). Guidelines for the Use of Antiretroviral Agents In HIV-1 Infected Adults And Adolescents. Department of Health and Human Services (DHHS) 2012.

 

Panel on Antiretroviral Therapy And Medical Management Of HIV-1 Infected Children (2012). Guidelines for The Use Of Antiretroviral Agents In Paediatric HIV Infection. Department of Health and Human Services (DHHS) 2012.

 

Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N (2000). Adherence to Protease Inhibitor Therapy And Outcomes In Patients With HIV Infection. Ann. Intern. Med. 133(1):21-30.
Crossref

 

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel, LM, Ndembi N, Hamers RL, Rinke De Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW (2015). HIV-1 Drug Resistance Mutations: Potential Applications for Point-Of-Care Genotypic Resistance Testing. PlosOne 10(12):E0145772.
Crossref

 

Roux P, Kouanfack C, Cohen J, Marcellin F, Boyer S, Delaporte E, Carrieri P, Laurent C, Spire B (2011). Adherence to Antiretroviral Treatment In HIV-Positive Patients In The Cameroon Context: Promoting The Use Of Medication Reminder Methods. J. Acquir. Immune. Defic. Syndr. 57(S1):S40-S43.
Crossref

 

Shuter J (2008). Forgiveness of Non-Adherence to HIV-1 Antiretroviral Therapy. J. Antimicrob. Chemother. 61(4): 769-773.
Crossref

 

Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS (2007). HIV-Infected Patients Receiving Lopinavir/Ritonavir-Based Antiretroviral Therapy Achieve High Rates Of Virologic Suppression Despite Adherence Rates Less Than 95%. J. Acquir. Immune. Defic. Syndr. 45(1): 4-8.
Crossref

 

Sohn AH, Hazra R (2013). The Changing Epidemiology Of The Global Paediatric HIV Epidemic: Keeping Track Of Perinatally HIV-Infected Adolescents. J. Int. AIDS Soc. 16(1):18555.
Crossref

 

Suaysod R, Ngo-Giang-Huong N, Salvadori N, Cressey TR, Kanjanavanit S, Techakunakorn P, Krikajornkitti S, Srirojana S, Laomanit L, Chalermpantmetagul S, Lallemant M, Le CS, Mcintosh K, Traisathit P, Jourdain G (2015). Treatment Failure in HIV-Infected Children On Second-Line Protease Inhibitor-Based Antiretroviral Therapy. Clin. Infect. Dis. 61(1):95-101.
Crossref

 

Taddeo D, Egedy M, Frappier JY (2008). Adherence to treatment in adolescents. Paediatr. Child Health 13(1):19-24.

 

Tang MW, Shafer RW (2012). HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications. Drugs 72(9):E1-25.
Crossref

 

Walsh JC, Mandalia S, Gazzard BG (2002). Responses To A 1 Month Self-Report On Adherence To Antiretroviral Therapy Are Consistent With Electronic Data And Virological Treatment Outcome. AIDS 16(2):269-277.
Crossref

 

Wensing AM, Van Maarseveen NM, Nijhuis M (2010). Fifteen Years Of HIV Protease Inhibitors: Raising The Barrier To Resistance. Antiviral Res. 85(1):59-74.
Crossref

 

World Health Organization (WHO) (2011). Joint United Nations Programme On HIV/AIDS (UNAIDS), United Nations International Childrens' Emergency Fund (UNICEF) (2011). Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access. 2011 Progress Report Geneva, Switzerland: World Health organization; 2011.

 

Wohl AR, Garland WH, Valencia R, Squires K, Witt MD, Kovacs A, Larsen R, Hader S, Anthony MN, Weidle PJ (2006). A Randomized Trial of Directly Administered Antiretroviral Therapy And Adherence Case Management Intervention. Clin. Infect. Dis. 42(11):1619-1627.
Crossref

 

World Health organization (WHO) (2014). Adolescent HIV Testing, Counselling And Care: Implementation Guidelines For Health Providers And Planners. Geneva, Switzerland.

 

World Health organization (WHO) (2010a). Antiretroviral Therapy For HIV Infection In Adults And Adolescents: Recommendations For A Public Health Approach (2010 Revision). Geneva, Switzerland.

 

World Health organization (WHO) (2010b). Antiretroviral Therapy For HIV Infection In Infants And Children: Recommendations For A Public Health Approach (2010 Revision). Geneva, Switzerland.

 

World Health organization (WHO) HIV/AIDS Programme (2013). Consolidated Guidelines On The Use Of Antiretroviral Drugs For Treating And Preventing HIV Infection. Recommendations For A Public Health Approach.

 

World Health organization (WHO) Multicentre Growth Reference Study Group (2007). WHO Child Growth Standards Based On Length/Height, Weight And Age. Acta Paediatr. 95(S450):76-85.

 


APA Chawana, T. D., Katzenstein, D., Nathoo, K., Ngara, B., & Nhachi, C. F. B. (2017). Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic. Journal of AIDS and HIV Research, 9(1), 17-30.
Chicago Tariro Dianah Chawana, David Katzenstein, Kusum Nathoo, Bernard Ngara and Charles Fungai Brian Nhachi. "Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic." Journal of AIDS and HIV Research 9, no. 1 (2017): 17-30.
MLA Tariro Dianah Chawana, et al. "Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic." Journal of AIDS and HIV Research 9.1 (2017): 17-30.
   
DOI 10.5897/JAHR2016.0406
URL http://academicjournals.org/journal/JAHR/article-abstract/24E08CE62105

Subscription Form